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MEKANISME KEMATIAN SEL CETUSAN 15-DEOXY 
PROSTAGLANDIN J2 DAN 17β-ESTRADIOL DALAM SEL 
KANSER PAYUDARA ER-POSITIF DAN ER-NEGATIF 
 
ABSTRAK 
 
Kanser payudara adalah kanser yang paling utama di kalangan wanita Malaysia. 
Peningkatan insiden penyakit ini di seluruh dunia menunjukkan kepentingan 
terhadap kajian untuk mengkaji dan mengenal pasti terapi yang lebih berkesan dan 
efektif untuk melawan kanser payudara. Penyelidikan terkini adalah kajian tindakan 
drug yang memberi kesan sampingan minimum dan juga memberi pemahaman yang 
lebih mendalam mengenai tindakan dan kerintangan sel tumor terhadap drug 
tersebut. Reseptor teraktif pemploriferasi peroksisom gamma (PPARγ) adalah 
reseptor nukleus bergantung pada ligand, yang dilaporkan nyatakan dalam pelbagai 
sel kanser termasuk payudara, prostat, kolorektal dan kanser pangkal rahim. Ligand 
untuk reseptor ini didapati telah merencat pertumbuhan sel kanser melalui apoptosis 
dan menghalang proliferasi akibat pengaktifan PPARγ. Walaupun begitu, peranan 
sebenar reseptor dan ligand ini, masih dalam kajian, terutama dalam sel kanser 
payudara. Kajian ini dilakukan untuk menyelidik kesan ligand endogenus PPARγ, 
iaitu 15 deoksi-prostaglandin J2 (15d-PGJ2) ke atas sel-sel kanser payudara manusia 
yang positif reseptor estrogen (ER) (MCF-7) dan negatif ER (MDA-MB-231) pada 
dengan kehadiran atau ketiadaan ligand ERα, iaitu 17 β-estradiol (E2). Kombinasi 
rawatan sel dengan 15d-PGJ2 dan E2 bertujuan untuk mengkaji hubungan 
pengisyaratan antara PPARγ dan ERα. Kajian sitotoksik menunjukkan bahawa 15d-
PGJ2 menghalang proliferasi sel MCF-7 dan MDA-MB-231 pada nilai EC50 antara 
15 dan 10 μM. Kajian berikutnya menunjukkan bahawa 15d-PGJ2 menghalang 
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proliferasi kedua-dua sel secara apoptosis melalui pengaktifan mitokondria. E2 
menggalakkan 15d-PGJ2 untuk meningkatkan apoptosis dalam sel  MCF-7 tetapi 
tidak pada sel MDA-MB-231. 15d-PGJ2 menyekat kitaran sel pada fasa G2/M dalam 
sel MCF-7 dan fasa G0/G1 dalam sel MDA-MB-231, tetapi E2 tidak memberi kesan 
kepada kitaran sel-sel tersebut. . Perbezaan pengekspresan mRNA dan protein ERα, 
PPARγ1 dan PPARγ2 dalam sel MCF-7 dan MDA-MB-231 kesan interaksi dua hala 
kedua-dua reseptor menyebabkan. Walaubagaimanapun, dengan menghalang 
pengaktifkan PPARγ, kami mendapati apoptosis yang diaruh oleh 15d-PGJ2 dalam 
kedua-dua sel tidak bergantung kepada pengaktifan reseptor PPARγ. Kajian 
seterusnya untuk mengenal pasti mekanisme apoptosis aruhan oleh 15d-PHJ2 
menunjukkan bahawa BAX memainkan peranan penting dalam mekanisme 
apoptosis yang diaruh oleh 15d-PGJ2 dengan kehadiran atau tanpa E2, tanpa 
melibatkan kaspase. Kajian terhadap molekul-molekul lain (Fas-Fasl dan p53) 
didapati memainkan peranan aktif dalam MDA-MB-231, tapi tidak dalam sel MCF-
7. Kajian selanjutnya perlu dijalankan untuk mengkaji mekanisme kematian sel-sel 
payudara secara apoptosis cetusan 15d-PGJ2 dengan kehadiran E2, yang tidak 
melibatkan PPARγ dan kaspase.  
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CELL DEATH MECHANISM INDUCED BY 15-DEOXY 
PROSTAGLANDIN J2 AND 17β-ESTRADIOL IN ER-POSITIVE 
AND ER-NEGATIVE BREAST CANCER CELL LINES 
 
ABSTRACT 
 
Breast cancer is the most common malignancy in Malaysian women. An increase in 
the prevalence of this disease worldwide indicates the necessity to explore and 
identify more potent and effective therapies against breast cancer. A number of 
studies are investigating drugs that cause no or minimal adverse effects and also 
focus on better understanding of the drug response and resistance by the tumour 
cells. Peroxisome proliferator-activated receptor gamma (PPARγ) is a ligand-
dependent nuclear receptor which is reported to be expressed in various cancer cells 
including breast, prostate, colorectal and cervical cancer. Ligands for this receptor 
have been found to inhibit various cancer cell growth by inducing apoptosis and 
attenuating cellular proliferation following PPARγ activation. The exact role of this 
receptor and its ligands, however, remains to be elucidated, especially in breast 
cancer cells. The present study was carried out to explore the effect of an 
endogenous ligand of PPARγ, 15 deoxy-Prostaglandin J2 (15d-PGJ2) on the estrogen 
receptor (ER)-positive (MCF-7) and ER-negative (MDA-MB-231) human breast 
cancer cells in the presence and absence of an ERα ligand, 17β-estradiol (E2). The 
combined treatment of cells with 15d-PGJ2 and E2 was aimed to explore the recently 
reported existence of signalling cross-talk between PPARγ and ERα. Cytotoxicity 
analysis showed that 15d-PGJ2 inhibited MCF-7 and MDA-MB-231 cells 
proliferation at EC50 values of 15 and 10 μM, respectively. Furthermore, 
experiments revealed that 15d-PGJ2 inhibited cell proliferation by inducing 
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apoptotic cell death in both cells with active involvement of mitochondria. E2 
potentiated 15d-PGJ2-induced apoptosis in MCF-7, but not in MDA-MB-231 cells. 
15d-PGJ2 arrested cell cycle at G2/M phase in MCF-7 and at G0/G1 phase in MDA-
MB-231, while E2 did not influence this cell cycle arrest in both cell lines. 
Differential mRNA and protein expressions of ERα and PPAR, γ1 and γ2 in MCF-7 
and MDA-MB-231 cells treated with 15d-PGJ2 in the presence and absence of E2 
suggested the existence of a bidirectional signal cross-talk between these receptors. 
However, by blocking the activation of PPARγ, we found that 15d-PGJ2 induced 
apoptosis in both cell lines independent of this receptor.  Further experiments 
performed to identify the mechanism of 15d-PGJ2-induced apoptosis in the presence 
and absence of E2 revealed caspase-independent apoptosis with a significant role of 
BAX in both cell lines. Other pro-apoptotic molecules investigated (Fas-FasL and 
p53) were found to play an active role in MDA-MB-231, but not in MCF-7 cells. 
Further experiments are needed to explore PPARγ- and caspase-independent 
apoptosis induced by15d-PGJ2 in breast cancer cells and the influence of E2 on this 
cell death mechanism.  
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INTRODUCTION 
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1.1   Cancer 
Cancer or malignant neoplasm is a genetic disease characterized by the uncontrolled 
growth and spread of abnormal cells. It is a disease of somatic cells that results from 
the accumulation of mutations within a genetically unstable heterogeneous cell 
population, leading to the emergence of a malignant subclone that has accumulated 
all of the functions necessary in solid tumours, such as invasion, metastasis and 
defeating the hosts’ defence. The three malignant properties of cancer cells; 
uncontrolled growth, invasion and metastasis, differentiate them from benign 
tumours, which are self limited and do not invade or metastasize (Chambers et al., 
2002).  
 
Each subclone population of cells evolves independently from others, competing for 
space and resources, such as oxygen and nutrients (Farber, 1984). Hanahan and 
Weinberg (2011) recently reported an upgraded list of ‘hallmarks of cancer’ which 
are the minimum set of genotypes or phenotypes that a cancer cell must acquire to 
become malignant. These are; (a)sustaining proliferative signaling, (b) evading 
growth suppressors, (c) resisting cell death, (d) enabling replicative immortality, (e) 
inducing angiogenesis, (f) activating invasion and metastasis, (g) reprogramming of 
energy metabolism and (h) evading immune destruction. Cells that accumulate 
some, but not all of these hallmarks or other changes necessary for malignancy are 
referred to as partially transformed.  
 
Almost all cancers are caused by abnormalities in the genetic material of the 
transformed cells. This can happen due to; external factors- tobacco smoke, 
radiation, chemicals, or infectious agents, and internal factors- mutations, hormones, 
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immune conditions and mutations that occur from metabolism (Meng and Riordan, 
2005). 
 
The genetic alterations observed in cancer cells are the manifestation of major 
chromosomal rearrangements (mutations) such as translocations, insertions, point 
mutations, deletions and/or gene amplification (Dixon and Kopras, 2004). Genes 
mostly affected by these mutations are oncogenes, tumour suppressor genes and the 
stability genes with the following characteristics (Strahm and Capra, 2005); 
 
Oncogenes –     Gain function and act in a dominant way.  
One mutant allele is required to change cellular behavior.  
Hyperactive growth and division. 
Protection against PCD. 
Loss of respect for normal cell boundaries. 
Ability to become established in diverse tissue environment. 
Example – Burkitt’s lymphoma gene (c-myc) 
 
Tumour suppressor genes – Inactivated and act in a recessive way.  
Both alleles of the gene must be inactivated to change cellular 
behavior.  
Loss of normal functions in those cells. 
Inaccurate DNA replication. 
Loss of control over cell cycle. 
Loss of orientation and adhesion within tissues. 
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Loss of interaction with protective cells of the immune 
system. 
Example – Retinoblastoma gene (Rb1) 
 
Stability genes -   Keep genetic alterations in general to a minimum. 
Prevent mutations in tumour suppressor genes and oncogenes. 
Alterations in both genes are required to result in a biological 
effect. 
Example – Ataxia teleangiectasia gene (ATM)                       
 
The proteins altered by these genetic changes include growth factors (GF) and 
growth factor receptors (GFR), signal transducers, kinase inhibitors and 
transcriptional factors (Meng and Riordan, 2005).  
 
 
1.2   Breast cancer 
Breast cancer is the second most common cancer after lung cancer and the top most 
common cancer in women worldwide. It comprises 10.4 % of all malignancies and 
18 % of all malignancies in women around the world, with the incidence ranging 
from an average of 95 per 100,000 in more developed countries to 20 per 100,000 in 
less developed countries (Imaginis Corporation, 2006). The incidence rate of breast 
cancer varies based on the variation in the risk factors. These factors can be broadly 
divided into established factors and possible risk factors. The established factors 
include a wide range of factors such as genetic susceptibility and family history, 
endogenous steroid hormone levels, age at menarche, age and type of menopause, 
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parity, age at first childbirth, height, weight, body size, and level of physical 
activity, lactation, alcohol consumption and use of exogenous hormone (hormone 
replacement therapy, combination oral contraceptives), while the possible risk 
factors mainly consist of insulin-like growth factors and dietary components 
including fat, fiber and soy (Henderson et al., 2003). 
 
Breast cancer was the commonest overall cancer (18 %) as well as the commonest 
cancer in women amongst all races from the age of 20 years in Malaysia for 2003 
and 2005. It is most common in the Chinese women population (59.7 per 100,000), 
followed by the Indians (55.8 per 100,000) and then, Malays (33.9 per 100,000). 
Breast cancer formed 31.1 % of newly diagnosed cancer cases in women in 2003 
(30.4 % in 2002) (National Cancer Registry, Malaysia, 2006). 
 
 
1.2.1   Genes involved in breast cancer 
Genetic mutations can be inherited (germline mutation) or acquired in a single cell 
during a person’s lifetime (somatic mutation), which is passed on to all other cells 
(Rieger, 2004). Inherited breast cancers are less common and occur when gene 
mutations are passed within a family, from one generation to the next, while somatic 
mutations can be caused by environmental factors, such as cigarette smoke, or other 
environmental carcinogens leading to sporadic cancer (www.cancer.net).  
 
Genetic mutations in certain types of genes are more likely to cause cancer. Several 
genes are linked to an increased risk of breast cancer. Mutations in these genes are 
associated with various hereditary syndromes. Some of the most common hereditary 
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cancer syndromes associated with breast cancer risk are described below (Greene, 
1997):  
 
Hereditary breast and ovarian cancer (HBOC) syndrome 
The two tumour suppressor genes associated with HBOC are BRCA1 and BRCA2 
(BReast CAncer 1 and 2). About 80 % of hereditary breast cancer is caused by 
mutations in these genes. Women who inherit BRCA1 and BRCA2 mutations have a 
50 % - 85 % chance of developing breast cancer and a 15 % - 40 % chance of 
developing ovarian cancer.  
 
Ataxia telangiectasia (A-T)  
 A-T is a rare recessive disorder inherited as an autosomal recessive condition. It is 
characterized by a progressive neurological problem that leads to difficulty in 
walking. The gene associated with A-T is called ATM (A-T mutated protein kinase). 
People with one altered copy of this gene, may have an increased risk of melanoma, 
breast, ovarian and stomach cancers. There is about a 40 % risk of cancer for people 
with A-T, the most common cancers being leukemia and lymphoma. With an 
increase in the lifespan of individuals with A-T, risk of other types of cancer, 
including melanoma, sarcoma, and breast, ovarian and stomach cancers, are 
increasingly reported.  
 
Cowden syndrome (CS)  
CS is a rare genetic condition caused by a mutation on the PTEN (phosphatase and 
tensin homologue deleted on chromosome 10) gene. Women with CS have a risk of 
developing breast cancer (25 % - 50 %) and also a risk of developing noncancerous 
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breast changes (65 %). People with CS also have a high risk of both non-cancerous 
and cancerous tumours of the thyroid and endometrium (lining of the uterus).  
 
Li-Fraumeni syndrome (LFS) 
LFS is a rare condition resulting from a mutation in a tumour suppressing gene, p53 
(protein 53). Another gene, CHEK2 (checkpoint homologue), may cause LFS for 
some families. People with LFS have up to a 50 % chance of developing cancer by 
the age of 40 and a 90 % chance of developing cancer by the age of 60. Some of the 
most common cancers associated with LFS are osteosarcoma, breast cancer, soft 
tissue sarcoma, leukemia, brain cancer, and adrenal cortical tumours.  
 
Peutz-Jeghers syndrome (PJS) 
The gene associated with PJS is a tumour suppressor gene called STK11 
(serine/threonine kinase 11). Women with PJS have a 50 % risk of developing breast 
cancer and about a 20 % risk of developing ovarian cancer. People with PJS often 
have multiple hamartomatous polyps, which are normal-appearing growths in the 
digestive tract (non-cancerous tumour). These polyps cause an increased risk of 
colorectal cancer.  
 
 
1.2.2    Classification of breast cancer 
Classification of breast cancer is performed in order to select which treatment 
approach should be taken to tackle this disease. Careful analysis of classification 
must be done so that these classifications can be tagged as true prognostic factors 
(estimate disease outcomes) or true predictive factors (estimate the likelihood of 
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response or lack of response to a specific treatment) (Gonzalez-Angulo et al., 2007).  
Breast cancer classification divides the cancer into various categories based on 
multiple different schemes, such as histopathological type, grade and stage of 
tumour and expression of different proteins and genes. A general overview of these 
classifications is as follows (Filho et al., 2011): 
 
1. Histopathology. Most of the breast cancers are classified as 
mammary ductal carcinoma and are derived from the epithelial lining 
of the lobules or ducts. Carcinoma in situ refers to cancer within the 
epithelial tissue without invasion to surrounding tissues whereas 
invasive carcinoma invades the surrounding tissues. A more 
aggressive form of breast cancer is achieved when the cancer invades 
the perineural and/or lymphovascular spaces.  
2. Stage. The breast cancer is staged based on TNM classification that 
measures the size of the cancer where it originally started and also the 
locations to which it metastasized. TNM refers to the size of tumour 
(T), if the tumour has spread to the lymph nodes (N) and if the 
tumour has metastazied (M). The main stages are: 
(a) Stage 0 – in situ disease. It is a pre-cancerous marker e.g. ductal 
carcinoma in situ, lobular carcinoma in situ etc. 
(b) Stage 1-3 – cancer restricted to the breast or regional lymph 
nodes but differes in size i.e., the higher the stage, the bigger the 
cancer. 
(c) Stage 4 – metastatic breast cancer with poor prognosis. 
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3.  Grade. Grading refers to the appearance of breast cancer cells 
compared to the appearance of normal breast tissues. A well 
differentiated cancer is termed as low grade tumour, a moderately 
differentiated one as intermediate grade and a poorly differentiated 
cancer as high grade tumour. Poorly differentiated cancers have a 
worse prognosis.  
4. Receptor status. Breast cancers are also classified based on various 
receptors either on the cell surface, cytoplasm and/or nucleus. The 
most important receptors in the breast carcinogenesis are estrogen 
receptors (ER), progesterone receptor (PR) and HER2/neu. Breast 
cancers that have these receptors are ER positive (+), PR+ or HER2+, 
and cancers that lack these receptors are classified as ER negative (-), 
PR- and HER2-. Cancer cells that lack all three receptors are called 
basal-like or triple negative which have a worse prognosis.  
 
 
1.2.3   Treatment of breast cancer 
With the advancements in research and development, a number of invasive and non-
invasive treatments for breast cancer have been in practice. Early diagnosis makes 
these treatments more effective, increasing the survival period of patients, or even 
controlling or eliminating the disease as such. Some of the most widely practiced 
treatments are listed below (Dolinsky, 2002): 
Surgery- Breast-conserving surgery (lumpectomy- removal of the tumour only and a 
small amount of surrounding tissue), mastectomy (removal of all of the breast 
tissue), and lymph node removal or axillary lymph node dissection, which can take 
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place during lumpectomy and mastectomy if the biopsy shows that breast cancer has 
spread outside the milk duct. Cryotherapy, also called cryosurgery, can also be 
performed that uses extreme cold to freeze and kill cancer cells. This treatment is an 
experimental treatment for breast cancer these days. Prophylactic mastectomy 
involves the removal of the breast to lower the risk of breast cancer in high-risk 
people. Prophylactic ovary removal is a preventive surgery that lowers the amount 
of estrogen in the body, making it harder for estrogen to stimulate the development 
of breast cancer. 
 
Chemotherapy- This treatment involves usage of medicine to weaken and destroy 
cancer cells in the body, including cells at the original cancer site and cancer cells 
that may have metastasized to other parts of the body. Chemotherapy is a systemic 
therapy, affecting the whole body through the bloodstream. In many cases, a 
combination of two or more medicines (chemotherapy regimens) is used as 
chemotherapy treatment for breast cancer. Chemotherapy is used to treat the early-
stage invasive breast cancer to get rid of any cancer cells that may be left behind 
after surgery and to reduce the risk of cancer recurrence, and in advanced breast 
cancer, chemotherapy regimens make the cancer shrink or disappear in about 30 % - 
60 % of people treated (Figure 1.1). Chemotherapeutic drugs have been classified 
into two major groups; Anthracyclines are chemically similar to an antibiotic. 
Anthracyclines damage the genetic material of cancer cells, which makes the cells, 
die. This group includes drugs such as Adriamycin, Ellence, and Daunorubicin. 
Taxanes interfere with the proliferation of cancer cells. Taxol, Taxotere, and 
Abraxane are taxanes. 
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Figure 1.1 Schematic representation of tumours responding or resistant to 
chemotherapy and changes in growth control (Adapted from Parton et 
al., 2001). 
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Hormonal therapy- Hormonal therapy medicines treat hormone receptor-positive 
breast cancers and are not effective against hormone receptor-negative breast 
cancers. These medicines work in two ways; lowering the amount of the hormone 
(estrogen) in the body, and by blocking the action of estrogen on breast cancer cells. 
 Estrogen, mostly made by the ovaries, potentiates the growth of hormone receptor-
positive breast cancers. Therefore, reducing the amount of this hormone or blocking 
its action can reduce the risk of early stage estrogen receptor (ER)-positive breast 
cancers recurring after surgery. Hormonal therapy medicines can also be used to 
help shrink or slow the growth of advanced stage or metastatic ER-positive breast 
cancers. There are several hormonal therapy medicines, including aromatase 
inhibitors (AI)- Arimidex, Aromasin and Femara, selective estrogen receptor 
modulators (SERMs)- Tamoxifen, Evista and Fareston, and estrogen receptor down 
regulators (ERDs)- Faslodex (Figure 1.2). 
 
Radiation therapy- It is a highly targeted and effective way to destroy cancer cells 
in the breast that may be present after surgery. Radiation therapy is relatively easy to 
tolerate with side effects limited to the treated area and can reduce the risk of breast 
cancer recurrence by about 70 %. There are two main types of radiation; external 
radiation is the most common type of radiation, typically given after lumpectomy 
and sometimes, mastectomy, while, internal radiation is a less common method of 
giving radiation. It is being studied for use after lumpectomy.  
 
Targeted therapy- Targeted cancer therapies are treatments that target specific 
features of cancer cells, such as a protein that allows the cancer cells to grow in a 
rapid or abnormal way. Generally, targeted therapies are less harmful to normal,  
13 
 
 
 
Estrogen Receptor 
Figure 1.2   Treatments for ER-positive breast cancer and chemoprevention that 
target specific domains of the estrogen receptor (Adapted from 
Nichols, 2007). 
The AIs inhibit the enzyme responsible for production of estradiol from androgenic 
precursors. SERMs compete with estradiol for binding to the ligand binding domain 
and alter the activator or repressor proteins that subsequently bind. Disulfide 
benzamide (DIBA) acts in a novel way, by interrupting the second zinc finger of the 
DNA binding domain, preventing receptor interaction at estrogen receptor response 
elements (Nichols, 2007). 
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healthy cells than chemotherapy. Some targeted therapies are antibodies that work 
like natural antibodies (immune targeted therapies). Currently three types of targeted 
therapies are under practice to treat breast cancer. These are; Herceptin 
(trastuzumab) works against HER2 (human epidermal GFR-2) -positive breast 
cancers by blocking the ability of the cancer cells to receive chemical signals that 
stimulate cell growth. Tykerb (lapatinib) works against HER2-positive breast 
cancers by interrupting with the HER2 pathway that can cause uncontrolled cell 
growth. Avastin (bevacizumab) works by blocking the growth of new blood vessels 
(angiogenesis) that cancer cells depend on to grow and function. 
 
 
1.3   Programmed Cell Death  
Balance between cell division and cell death is one of the most important 
mechanisms for the development and maintenance of multicellular organism. 
Disorders in either of these processes have pathological consequences that can lead 
to various diseases, such as cancer. This equilibrium between cell death and cell 
proliferation is tightly controlled by a process called programmed cell death or PCD 
(Broker et al., 2005). PCD is a well defined and characterized set of events 
counteracting tumour growth and plays a critical role in a wide variety of 
physiological processes during fetal development and also in adults. In the past 
decades, PCD was held synonymous with apoptosis, which now has been classified 
as a type of PCD.  
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The Nomenclature Committee on Cell Death (NCCD) proposed a list of molecular 
or morphological criteria necessary for a cell to be considered dead (Kroemer et al., 
2009). These are; 
1. The cell has lost the integrity of its plasma membrane.  
2. The cell, including its nucleus, has undergone complete fragmentation 
into discrete bodies (referred to as apoptotic bodies). 
3. The cell’s fragments have been engulfed by an adjacent cell in vivo. 
 
Thus, bona fide dead cells would be different from dying cells that have not yet 
concluded their demise (Table 1.1).  
 
 
1.3.1   Classification of PCD  
Participation of active cellular processes that can be intercepted by interfering with 
intracellular signalling is the foremost criterion for PCD (active cell death) (Leist 
and Jaattela, 2001). Due to its complex mechanism and intervening of different 
molecules, classification of PCD has always been a topic of debate among 
researchers. Only recently it has been found that PCD is not limited to the 
previously characterized apoptosis, but it can also occur in a well programmed 
manner in the complete absence of caspases (cysteinyl-aspartic acid proteases) or 
other apoptotic molecules without inducing accidental cell death (Broker et al., 
2005). 
 
A number of studies have been carried proposing different types of PCD. Despite 
numerous models proposed to categorize PCD, exclusive definition of different  
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Table 1.1   Cell death methodology (Kroemer et al., 2009). 
 
Definition Explanation Methods of detection 
Molecular or morphological criteria to define dead cells 
Loss of plasma membrane 
integrity 
Plasma membrane has 
broken down, resulting in 
the loss of cell’s identity 
 IF microscopy and/or 
FACS to assess the 
exclusion of vital dyes, in 
vitro 
Cell fragmentation The cell (including its 
nucleus) has undergone 
complete fragmentation 
into discrete bodies 
(usually referred to as 
apoptotic bodies) 
IF microscopy, FACS 
quantification of 
hypodiploid events (sub-
G1 peak) 
Engulfment by adjacent 
cells 
The corpse or its 
fragments have been 
phagocytosed by 
neighboring cells 
IF microscopy, FACS 
colocalization studies 
Proposed points-of-no-return to define dying cells 
Massive activation of 
caspases 
Caspases execute the 
classic apoptotic 
programme, yet in several 
instances, caspase-
independent death occurs. 
Moreover, caspases are 
involved in non-lethal 
processes including 
differentiation and 
activation of cells 
Immunoblotting, FACS 
quantification by means of 
fluorogenic substrates or 
specific antibodies 
∆Ψm dissipation Protracted ∆Ψm loss 
usually precedes MMPand 
cell death; however, 
transient dissipation is not 
always a lethal event 
FACS quantification with 
∆Ψm –sensitive probes, 
Calcein-cobalt techniques 
MMP Complete MMP results in 
the liberation of lethal 
catabolic enzymes or 
activators of such 
enzymes. Nonetheless, 
partial permeabilization 
may not necessarily lead 
to cell death 
IF colocalization studies, 
Immunoblotting after 
subcellular fractionation 
PS exposure 
 
 
 
 
PS exposure on the outer 
leaflet of the plasma 
membrane often is an 
early event of apoptosis, 
but may be reversible. PS 
exposure occurs also in T-
cell activation, without 
cell death 
FACS quantification of 
Annexin-V binding 
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Definition Explanation Modes of detection 
Operative definition of cell death, in particular in cancer research 
Loss of clonogenic 
survival 
This method does not 
distinguish cell death from 
long-lasting or irreversible 
cell cycle arrest 
Clonogenic assays 
 
 
Abbreviations: ∆Ψm- mitochondrial transmembrane permeabalization; FACS- 
fluorescence-activated cell sorter; IF- immunofluorescence; MMP- mitochondrial 
membrane permeabilization; PS- phosphotidylserine 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1.1   Continued. 
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types of PCD is difficult to due to the overlapping of signalling pathways between 
different death mechanisms. However, specific definitions of PCD have been put 
forth based on certain distinct features observed within the cells during PCD. The 
NCCD proposed a list of different types of PCD describing distinct modalities of 
cell death in their 2009 review of make Classification of cell death: 
recommendations of the Nomenclature Committee on Cell Death 2009 (Kroemer et 
al., 2009). They classified PCD into Typical (Table 1.2; Figure 1.3) and Atypical 
cell death modalities, which are briefly described below.  
 
Typical cell death modalities 
1.  Apoptosis 
Apoptosis or type I cell death is an inherent, controlled cell death programme 
characterized by cell death with specific morphological features, such as cell 
shrinkage, condensation of the chromatin and disintegration of the cells into 
small fragments that can be engulfed by nearby cells without inciting 
inflammation (Kerr et al., 1972; Strasses et al., 2000; Ferri and Kroemer, 
2001; Kaufmann and Hengartner, 2001). Apoptosis will be described in 
detail later in the current chapter.  
 
2. Autophagy 
Autophagy is a cellular catabolic degradation response to starvation or stress, 
whereby cellular proteins, cytoplasm and organelles are engulfed, digested 
and recycled to sustain cellular metabolism. It is a genetically programmed 
and evolutionary conserved process that degrades long lived cellular proteins 
and organelles (Clarke, 1990). Autophagic cell death is characterized by  
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Table 1.2   Distinct modalities of a typical PCD (Kroemer et al., 2009). 
 
Mode of PCD Morphological features 
Apoptosis Rounding up of the cell 
Retraction of presudopods 
Reduction of the cellular and nuclear volume (pyknosis) 
Nuclear fragmentation (karyorrhexis) 
Minor modification of cytoplasmic organelles 
Plasma membrane blebbing 
Engulfment by neighboring phagocytes in vivo 
Autophagy Lack of chromatin condensation 
Massive vacuolization of the cytoplasm 
Accumulation of double membrane, autophagic vacuoles 
Little or no uptake by phagocytic cells in vivo 
Cornification Elimination of cytosolic organelles 
Modifications of plasma membrane 
Accumulation of lipids in F and L granules 
Extrusion of lipids in the extracellular space 
Desquamation or loss of corneocytes by protease activation  
Necrosis Cytoplasmic swelling (oncosis) 
Rupture of plasma membrane 
Swelling of cytoplasmic organelles 
Moderate chromatin condesation 
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Figure 1.3   Distinct modalities of a typical PCD (Adapted from Jaattela et al., 
2004). 
 
 
Caspase 8 and cathepsin can cleave and activate a BH-3 only protein, BID, while 
disruption of the cytoskeleton leads to the release of BH-3 only proteins BIM and 
BMF which can activate the pore forming proteins, BAX and/or BAK. Activation of 
JNK pathway increases the expression of BMF and HRK, whereas, DNA damage 
induces a p53-mediated transcription of genes encoding BAX as well as proteins 
involved in ROS generation. Endoplasmic reticulum stress results in the release of 
Ca2+, which may cause mitochondrial damage directly, or activate BAX via calpain-
mediated cleavage. BNIP3 is activated by acidosis, which is translocated to the 
mitochondrial membrane. Mitochondrial damage leads to the release of numerous 
mitochondrial proteins that trigger the execution of PCD, such as cyto c, 
Smac/Diablo, EndoG and Omi/HtrA2 which trigger caspase activation and classical 
apoptosis. AIF triggers caspase-independent apoptosis, while Ca2+ and ROS can lead 
to severe mitochondrial dysfunction and necrosis-like PCD and in certain cases, 
autophagy (Jaattela et al., 2004). 
 
 
 
